Skip to content
value.today

Zymeworks Inc.: insider trading

112 trades by 14 directors, officers and 10% owners since 2022, from their SEC Form 4 and 5 filings.

Bought, 12 months
$0
0 purchases by 0 insiders
Sold, 12 months
$6.4 M
15 sales by 6 insiders
Bought, 3 months
$0
0 purchases
Sold, 3 months
$1.8 M
5 sales

Insider buying and selling by month

Open-market purchases and sales by value, last three years.

$18.9 M-$3.4 M$0Dec 2023: bought $0 (0 trades), sold $8 K (1 trades)Dec 23Jan 2024: bought $0 (0 trades), sold $428 K (6 trades)Dec 2024: bought $4.9 M (5 trades), sold $0 (0 trades)DecJan 2025: bought $9.6 M (8 trades), sold $1.3 M (5 trades)Mar 2025: bought $18.9 M (12 trades), sold $0 (0 trades)MarApr 2025: bought $6.5 M (6 trades), sold $0 (0 trades)May 2025: bought $636 K (2 trades), sold $0 (0 trades)MayDec 2025: bought $0 (0 trades), sold $1.3 M (1 trades)Jan 2026: bought $0 (0 trades), sold $3.4 M (9 trades)Jan 26Oct 2026: bought $0 (0 trades), sold $358 K (1 trades)Nov 2026: bought $0 (0 trades), sold $1.4 M (4 trades)Nov
Bought (open market)Sold (open market)Hover a month for the totals

Insiders (14)

Each insider's latest direct holding and their open-market trades of the last 12 months, most recent first.

Zymeworks Inc. insiders
InsiderShares owned directlyBought, 12 mSold, 12 mLatest trade
Scott PlatshonEVP, Chief Business Officer21,745—$382 K
Paul Andrew MooreChief Scientific Officer33,756—$1.8 M
Adam SchayowitzEVP, Head of R&D23,205—$358 K
Mark HollywoodEVP & Chief Operating Officer133,852—$139 K
Jeffrey T. L. SmithEVP & Chief Medical Officer26,708—$476 K
Kenneth GalbraithChair & CEO, Director226,842—$3.3 M
Leone D. PattersonEVP, Chief Bus & Fin Officer459——
Gregory Austin CiongoliDirector488,500——
Oleg NodelmanDirector, 10% owner———
EcoR1 Capital, LLCDirector, 10% owner———
Christopher AstleSVP & Chief Financial Officer6,503——
Neil A. KlompasPresident & COO17,032——
Neil JosephsonChief Medical Officer14,449——
Redmile Group, LLC10% owner———

Trades#

Zymeworks Inc.: insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Scott PlatshonEVP, Chief Business OfficerSell-15,292$24.95$382 K21,745Form 4
filed Paul Andrew MooreChief Scientific OfficerSell-7,367$26.14$193 K66,130Form 4
filed Paul Andrew MooreChief Scientific OfficerSell-7,374$26.09$192 K58,756Form 4
filed Paul Andrew MooreChief Scientific OfficerSell-25,000$26.04$651 K33,756Form 4
filed Adam SchayowitzEVP, Head of R&DSell-13,832$25.85$358 K23,205Form 4
filed Mark HollywoodEVP & Chief Operating OfficerSell-6,120$22.67$139 K132,913Form 4
filed Kenneth GalbraithChair & CEO, DirectorSell-30,424$22.67$690 K226,842Form 4
filed Paul Andrew MooreChief Scientific OfficerSell-9,560$22.67$217 K48,497Form 4
filed Jeffrey T. L. SmithEVP & Chief Medical OfficerSell-9,310$22.67$211 K26,708Form 4
filed Kenneth GalbraithChair & CEO, DirectorSell-22,657$25.10$569 K158,286Form 4
filed Paul Andrew MooreChief Scientific OfficerSell-9,289$25.10$233 K31,212Form 4
filed Jeffrey T. L. SmithEVP & Chief Medical OfficerSell-10,538$25.10$265 K18,352Form 4
filed Kenneth GalbraithChair & CEO, DirectorSell-31,686$25.10$795 K193,266Form 4
filed Paul Andrew MooreChief Scientific OfficerSell-10,821$25.10$272 K40,391Form 4
filed Kenneth GalbraithChair & CEO, DirectorSell-47,528$27.02$1.3 M133,275Form 4
filed Paul Andrew MooreChief Scientific OfficerSell-9,792$14.92$146 K14,741Form 4
filed Jeffrey T. L. SmithEVP & Chief Medical OfficerSell-11,110$14.92$166 K8,890Form 4
filed Kenneth GalbraithChair & CEO, DirectorSell-23,885$14.92$356 K47,543Form 4
filed Kenneth GalbraithChair & CEO, DirectorSell-33,406$14.92$498 K80,803Form 4
filed Paul Andrew MooreChief Scientific OfficerSell-11,408$14.92$170 K23,333Form 4
filed Paul Andrew MooreChief Scientific OfficerSell-2,339$11.22$26 K7,367Form 4
filed Christopher AstleSVP & Chief Financial OfficerSell-1,431$11.22$16 K6,503Form 4
filed Kenneth GalbraithChair & CEO, DirectorSell-5,706$11.22$64 K23,762Form 4
filed Kenneth GalbraithChair & CEO, DirectorSell-18,198$10.65$194 K29,468Form 4
filed Paul Andrew MooreChief Scientific OfficerSell-7,460$10.65$79 K9,706Form 4
filed Christopher AstleSVP & Chief Financial OfficerSell-4,563$10.65$49 K7,934Form 4
filed Christopher AstleSVP & Chief Financial OfficerSell-886$9.130$8 K1,997Form 4
filed Neil A. KlompasPresident & COOSell-2,977$7.830$23 K17,032Form 4
filed Christopher AstleSVP & Chief Financial OfficerSell10b5-1 plan · amended-887$6.010$5 K1,333Form 4/A
filed Christopher AstleSVP & Chief Financial OfficerSell10b5-1 plan-887$6.010$5 K1,333Form 4
filed Neil JosephsonChief Medical OfficerSell10b5-1 plan · amended-2,475$8.100$20 K14,449Form 4/A
filed Neil JosephsonChief Medical OfficerSell10b5-1 plan-2,475$8.100$20 K14,449Form 4

Source: SEC Forms 4 and 5. A trade under a 10b5-1 plan was scheduled in advance. For information only; not investment advice